GH Research (NASDAQ:GHRS) Shares Up 6.8%

GH Research PLC (NASDAQ:GHRS) shares rose 6.8% on Monday . The stock traded as high as $11.79 and last traded at $11.78. Approximately 53,825 shares traded hands during trading, a decline of 60% from the average daily volume of 135,350 shares. The stock had previously closed at $11.03.

Wall Street Analyst Weigh In

GHRS has been the topic of several recent analyst reports. JMP Securities lowered their target price on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a research report on Friday, March 1st. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Monday, March 4th.

GH Research Price Performance

The firm’s 50-day moving average price is $9.85 and its 200 day moving average price is $7.84.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Sell-side analysts predict that GH Research PLC will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several institutional investors and hedge funds have recently modified their holdings of GHRS. RTW Investments LP lifted its stake in shares of GH Research by 53.4% during the third quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock valued at $33,438,000 after buying an additional 1,158,172 shares during the period. BVF Inc. IL lifted its stake in shares of GH Research by 12.1% during the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after buying an additional 1,125,000 shares during the period. Lynx1 Capital Management LP lifted its stake in shares of GH Research by 13.8% during the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after buying an additional 133,804 shares during the period. Barclays PLC lifted its stake in shares of GH Research by 98.2% during the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after buying an additional 31,500 shares during the period. Finally, PEAK6 Investments LLC lifted its stake in shares of GH Research by 72.9% during the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock valued at $405,000 after buying an additional 16,991 shares during the period. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).